<DOC>
	<DOCNO>NCT00119171</DOCNO>
	<brief_summary>The purpose study determine dose regimen Ispinesib combination capecitabine patient solid tumor . Ispinesib dose 1-hour intravenous infusion every 3 week capecitabine dose orally , twice day 14 day 1 week rest period . A patient may continue receive treatment long benefiting treatment . Blood sample take specific time measure amount drug body specific time drug give . Blood sample also take lab test complete blood count clinical chemistry . Physical exam perform treatment Ispinesib . During treatment phase , patient undergo regular assessment safety clinical response .</brief_summary>
	<brief_title>Ispinesib In Combination With Capecitabine In Patients With Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Inclusion criterion : Histologically cytologically confirm diagnosis advance solid tumor malignancy responsive standard therapy standard therapy . ECOG ( Eastern Cooperative Oncology Group ) Performance Status 02 . Bone marrow function : ANC great 1500/mm3 . Platelet count great equal 100,000/mm3 . Hemoglobin great 9 g/dL . Renal function : Calculated creatinine clearance great equal 50 mL.min . Total bilirubin great 1.5 mg/dL . AST/ALT le 2.5 X upper limit normal . Exclusion criterion : Females pregnant nursing . Preexisting hemolytic anemia . Preexisting peripheral neuropathy great equal grade 2 . Known deficiency dihydropyrimidine dehydrogenase ( DSD ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Safety</keyword>
	<keyword>tolerability</keyword>
	<keyword>dose limit toxicity</keyword>
	<keyword>solid tumor</keyword>
	<keyword>capecitabine</keyword>
</DOC>